Skip to content

Scholar Rock SRRK Debt-to-assets

Debt-to-assets at other companies

Biogen logo
BiogenBIIB
0.2×0.0×
PTC Therapeutics logo
PTC TherapeuticsPTCT
0.1×0.0×
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-0.1×
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
0.0×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
2.4×+2.4×
Arrowhead Research logo
Arrowhead ResearchARWR
0.0×

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Cash & equivalents$430.5M+212%
Total debt$205.7M+226%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
CapEx$68.0K-74.9%
Free cash flow-$82.2M-4.1%

Valuation

See full
Market cap$5.67B+85.5%
Enterprise value$5.45B+82.6%
P/S170.9×

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-138.9%+60.1pp
Debt / equity0.7×+0.5×
Current ratio8.6×-1.6×

Where this comes from

Calculated from Scholar Rock’s reported figures.

Based on the most recent quarter.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's debt-to-assets?
Scholar Rock (SRRK) reported debt-to-assets of 0.4× in Q1 2026.
How has Scholar Rock's debt-to-assets changed year-over-year?
Scholar Rock's debt-to-assets increased by 148.1% year-over-year, from 0.2× to 0.4×.
What is the long-term trend for Scholar Rock's debt-to-assets?
Over 5 years (2020 to 2025), Scholar Rock's debt-to-assets has grown at a 12.9% compound annual growth rate (CAGR), from 0.1× to 0.3×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.